← 返回前沿论文

NK 细胞来源外泌体通过递送顺铂并重新激活 NK 细胞功能增强对卵巢癌的抗肿瘤效应

英文原题:NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions.

PubMed 2023/01/19(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

研究概要

eNK-EXO 自身即具有针对卵巢癌的抗肿瘤活性,可用于递送顺铂并增强其对耐药卵巢癌细胞的细胞毒作用,还能逆转 NK 细胞的免疫抑制,这或许使 eNK-EXO 在临床治疗卵巢癌方面具有广阔前景。

中文摘要

外泌体是几乎所有细胞主动分泌的膜性囊泡,可向靶细胞递送包括核酸、蛋白质和脂质在内的某些细胞内分子。由于生物相容性好、通透性高、免疫原性低且毒性低,外泌体也被认为是良好的药物递送载体。已有报告显示,免疫细胞来源外泌体具有免疫调节活性。本研究评估扩增NK 细胞来源外泌体(eNK-EXO)治疗卵巢癌(OC)的应用。研究显示,eNK-EXO表达NK细胞典型蛋白标志物,可被SKOV3细胞优先摄取,并对OC细胞具有细胞毒性。此外,负载顺铂的eNK-EXO可使耐药OC细胞对顺铂抗增殖作用重新敏感。研究还显示,eNK-EXO可活化免疫抑制性肿瘤微环境中的NK细胞,并通过转录分析探讨了其机制。总之,eNK-EXO本身对OC具有抗肿瘤活性,可用作顺铂载体并增强其对耐药OC细胞的细胞毒作用,同时逆转NK细胞免疫抑制,因此其临床治疗OC具有很大前景。本研究也为进一步评估eNK-EXO用于其他实体瘤治疗奠定了坚实基础。

展开英文摘要原文

Exosomes are membranous vesicles actively secreted by almost all cells and they deliver certain intracellular molecules, including nucleic acids, proteins, and lipids, to target cells. They are also considered to be good carriers for drug delivery due to their biocompatibility, high permeability, low immunogenicity, and low toxicity. Exosomes from immune cells were also reported to have immunomodulatory activities. Herein we evaluated the application of exosomes derived from expanded natural killer cells (eNK-EXO) for the treatment of ovarian cancer (OC). We demonstrate that eNK-EXO express typical protein markers of natural killer (NK) cells, can be preferentially uptaken by SKOV3 cells, and display cytotoxicity against OC cells. Furthermore, eNK-EXO loaded with cisplatin could sensitize drug-resistant OC cells to the anti-proliferation effect of cisplatin. In addition, we show that eNK-EXO could activate NK cells from immunosuppressive tumor microenvironment, the mechanism of which is explored by transcriptional analysis. In summary, eNK-EXO exhibit anti-tumor activity against OC on its own, could be used to deliver cisplatin and enhance its cytotoxic effect against drug-resistant OC cells and also reverse the immunosuppression of NK cells, which may lead to great prospect of using eNK-EXO in the treatment of OC in the clinic. Our work also builds a strong foundation for further evaluation of eNK-EXO in other solid tumor therapies.

论文信息

作者
Luo H、Zhou Y、Zhang J、Zhang Y、Long S、Lin X、Yang A、Duan J
单位
Tissue Engineering and Stem Cell Experiment Center, Guizhou Medical University (GMU), Guiyang, Guizhou, China.China
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 36741396 · DOI 10.3389/fimmu.2022.1087689